Yanhong Gu

4.5k citations
120 papers · 3.3k · h-index 33

Impact in

  • Immunology top 5%
    • Immune Cell Function and Interaction
    • Immunotherapy and Immune Responses
    • interferon and immune responses
    • Immune cells in cancer
  • Oncology top 2%
    • Cancer Immunotherapy and Biomarkers
    • CAR-T cell therapy research

Papers in

  • Oncology 53
    • Cancer Immunotherapy and Biomarkers 17
    • Colorectal Cancer Treatments and Studies 13
  • Molecular Biology 34
    • Extracellular vesicles in disease 8
    • Inflammasome and immune disorders 6
Co-authors
Qiang Xu (45 shared papers)Yang Sun (31 shared papers)Wenjie Guo (26 shared papers)Yan Shen (17 shared papers)Yongqian Shu (26 shared papers)Xingxin Wu (11 shared papers)Peifen Cai (9 shared papers)Xuefeng Wu (10 shared papers)
Journals
Journal of Clinical Oncology (11 papers)Biomedicine & Pharmacotherapy (9 papers)Cell Death and Disease (6 papers)Toxicology and Applied Pharmacology (6 papers)Medicine (5 papers)
Partner nations
ChinaUnited StatesCzechia

In The Last Decade

Yanhong Gu

118 papers receiving 3.3k citations

Peers

Yanhong Gu
Comparison fields: 5 of 116
  • Immunology 817
  • Oncology 896
  • Cancer Research 369
  • Complementary and alternative medicine 194
  • Molecular Biology 1.4k
Replace Shoichi Hazama with:
Shoichi Hazama Japan
Wen Peng China
Zhi Zeng China
Min Xu China
Pankaj Gupta India
Minjiang Chen China
Pengfei Yu China
Shuai Zhang China
Jinhua Xu China
Quansheng Zhou China
Yanhong Gu relative to Shoichi Hazama Japan Shoichi Hazama's profile →
Citations per field
00.5×2×3×3.9×
Shoichi Hazama · 1×
Citations per year

Countries citing papers authored by Yanhong Gu

Since Specialization
Citations

This map shows the geographic impact of Yanhong Gu's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Yanhong Gu with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Yanhong Gu more than expected).

Fields of papers citing papers by Yanhong Gu

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Yanhong Gu. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Yanhong Gu. The network helps show where Yanhong Gu may publish in the future.

Co-authors

The 25 scholars most cited alongside Yanhong Gu, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.

Border = papers with Yanhong Gu Line = papers co-authored together Yanhong Gu links everyone, so they are left out of the graph.

All Works

20 of 20 papers shown

Showing the 20 most-cited of 120 papers — load more, or switch the sort, to bring in the rest.

#Work
1
Small molecule-driven mitophagy-mediated NLRP3 inflammasome inhibition is responsible for the prevention of colitis-associated cancer
Autophagy ·Wenjie Guo, Yang Sun, Wen Liu, Xingxin Wu, Lele Guo, Peifen Cai, Xuefeng Wu, Xudong Wu, Yan Shen, Yongqian Shu, Yanhong Gu, Qiang Xu
2014247
2
Inhibition of AIM2 inflammasome-mediated pyroptosis by Andrographolide contributes to amelioration of radiation-induced lung inflammation and fibrosis
Cell Death and Disease ·Jian Gao, Shuang Peng, Xinni Shan, Guoliang Deng, Lihong Shen, Jian Sun, Chunhong Jiang, Xiaoling Yang, Zhigang Chang, Xinchen Sun, Fude Feng, (unknown), Yanhong Gu, Wenjie Guo, Qiang Xu, Yang Sun
2019155
3
A novel benzo[d]imidazole derivate prevents the development of dextran sulfate sodium-induced murine experimental colitis via inhibition of NLRP3 inflammasome
Biochemical Pharmacology ·Wen Liu, Wenjie Guo, Jing Wu, Qiong Luo, Feifei Tao, Yanhong Gu, Yan Shen, Jian‐Xin Li, Renxiang Tan, Qiang Xu, Yang Sun
2013129
4
Tyrosine phosphatase SHP2 negatively regulates NLRP3 inflammasome activation via ANT1-dependent mitochondrial homeostasis
Nature Communications ·Wenjie Guo, Wen Liu, Zhen Chen, Yanhong Gu, Shuang Peng, Lihong Shen, Yan Shen, Xingqi Wang, Gen‐Sheng Feng, Yang Sun, Qiang Xu
2017118
5
A Phase Ib Study of Pembrolizumab as Second-Line Therapy for Chinese Patients With Advanced or Metastatic Melanoma (KEYNOTE-151)
Translational Oncology ·Lu Si, Xiaoshi Zhang, Yongqian Shu, Hongming Pan, Di Wu, Jiwei Liu, Fang Lou, Lili Mao, Xuan Wang, Xizhi Wen, Yanhong Gu, Lingjun Zhu, Shijie Lan, Xin Cai, Scott J. Diede, Yu Zhou, Jun Ge, Jianfeng Li, Haiyan Wu, Jun Guo
201999
6
Sorafenib inhibits activation of human peripheral blood T cells by targeting LCK phosphorylation
Leukemia ·Wei Zhao, Yanhong Gu, Ran Song, Bingqian Qu, Qiang Xu
200886
7
Andrographolide reversed 5-FU resistance in human colorectal cancer by elevating BAX expression
Biochemical Pharmacology ·Weicheng Wang, Wenjie Guo, Lele Li, Zan Fu, Wen Liu, Jian Gao, Yongqian Shu, Qiang Xu, Yang Sun, Yanhong Gu
201683
8
A Novel Disease-Modifying Antirheumatic Drug, Iguratimod, Ameliorates Murine Arthritis by Blocking IL-17 Signaling, Distinct from Methotrexate and Leflunomide
The Journal of Immunology ·Qiong Luo, Yang Sun, Wen Liu, Qian Cheng, Biaobing Jin, Feifei Tao, Yanhong Gu, Xingxin Wu, Yan Shen, Qiang Xu
201382
9
Andrographolide sulfonate ameliorates experimental colitis in mice by inhibiting Th1/Th17 response
International Immunopharmacology ·Wen Liu, Wenjie Guo, Lele Guo, Yanhong Gu, Peifen Cai, Ning Xie, Xiaoling Yang, Yongqian Shu, Xuefeng Wu, Yang Sun, Qiang Xu
201476
10
Targeting Sarcoplasmic/Endoplasmic Reticulum Ca2+-ATPase 2 by Curcumin Induces ER Stress-Associated Apoptosis for Treating Human Liposarcoma
Molecular Cancer Therapeutics ·Lu Wang, Lingxian Wang, Ran Song, Yan Shen, Yang Sun, Yanhong Gu, Yongqian Shu, Qiang Xu
201174
11
SHP2-Mediated Inhibition of DNA Repair Contributes to cGAS–STING Activation and Chemotherapeutic Sensitivity in Colon Cancer
Cancer Research ·Bin Wei, Lingyan Xu, Wenjie Guo, Yuanyuan Wang, Jingjing Wu, Xiaofei Li, Xiaomin Cai, Jinbo Hu, Meijing Wang, Qiang Xu, Wen Liu, Yanhong Gu
202169
12
Combination of Fruquintinib and Anti–PD-1 for the Treatment of Colorectal Cancer
The Journal of Immunology ·Yuanyuan Wang, Bin Wei, Jianhua Gao, Xiaomin Cai, Lingyan Xu, Haiqing Zhong, Binglin Wang, Yang Sun, Wenjie Guo, Qiang Xu, Yanhong Gu
202064
13
Neoadjuvant sintilimab and chemotherapy in patients with potentially resectable esophageal squamous cell carcinoma (KEEP-G 03): an open-label, single-arm, phase 2 trial
Journal for ImmunoTherapy of Cancer ·Xiaofeng Chen, Xiang Xu, Danping Wang, Jinyuan Liu, Jing Ping Sun, Mingjie Lu, Rui Wang, Bingqing Hui, Xiaofei Li, Chenchen Zhou, Min Wang, Tianzhu Qiu, Shiyun Cui, Nana Sun, Yang Li, Fufeng Wang, Cuicui Liu, Yang Shao, Jinhua Luo, Yanhong Gu
202360
14
Long Noncoding RNA MALAT1 Contributes to Sorafenib Resistance by Targeting miR-140-5p/Aurora-A Signaling in Hepatocellular Carcinoma
Molecular Cancer Therapeutics ·Lei Fan, Xiang Huang, Jing Chen, Kai Zhang, Yanhong Gu, Jing Sun, (unknown)
202060
15
CXCL10-armed oncolytic adenovirus promotes tumor-infiltrating T-cell chemotaxis to enhance anti-PD-1 therapy
OncoImmunology ·Xiaofei Li, Mingjie Lu, Manman Yuan, Jing Ye, Wei Zhang, Lingyan Xu, Xiaohan Wu, Bingqing Hui, Yuchen Yang, Bin Wei, Ciliang Guo, Min Wei, Jie Dong, Xingxin Wu, Yanhong Gu
202260
16
Beauvericin Ameliorates Experimental Colitis by Inhibiting Activated T Cells via Downregulation of the PI3K/Akt Signaling Pathway
PLoS ONE ·Xuefeng Wu, Rui Xu, (unknown), Qian Cheng, Yan Shen, Xudong Wu, Yanhong Gu, Qiang Xu, Yang Sun
201356
17
Erlotinib inhibits T-cell-mediated immune response via down-regulation of the c-Raf/ERK cascade and Akt signaling pathway
Toxicology and Applied Pharmacology ·Qiong Luo, Yanhong Gu, Wei Zheng, Xingxin Wu, Fang‐Yuan Gong, Liyun Gu, Yang Sun, Qiang Xu
201154
18
DNA damage repair promotion in colonic epithelial cells by andrographolide downregulated cGAS‒STING pathway activation and contributed to the relief of CPT-11-induced intestinal mucositis
Acta Pharmaceutica Sinica B ·Yuanyuan Wang, Bin Wei, Danping Wang, Jingjing Wu, Jianhua Gao, Haiqing Zhong, Yang Sun, Qiang Xu, Wen Liu, Yanhong Gu, Wenjie Guo
202154
19
Axitinib augments antitumor activity in renal cell carcinoma via STAT3-dependent reversal of myeloid-derived suppressor cell accumulation
Biomedicine & Pharmacotherapy ·Huaqin Yuan, Peifen Cai, Qian Li, Weicheng Wang, Yang Sun, Qiang Xu, Yanhong Gu
201451
20
Novel role of Sarco/endoplasmic reticulum calcium ATPase 2 in development of colorectal cancer and its regulation by F36, a curcumin analog
Biomedicine & Pharmacotherapy ·Lu Fan, Ang Li, Wanshuai Li, Peifen Cai, Baofang Yang, Minxia Zhang, Yanhong Gu, Yongqian Shu, Yang Sun, Yan Shen, Xuefeng Wu, Gang Hu, Xudong Wu, Qiang Xu
201451

About Yanhong Gu

Yanhong Gu is a scholar working on Oncology, Molecular Biology, Immunology, Pulmonary and Respiratory Medicine and Cancer Research, having authored 120 papers that have together received 3.3k indexed citations. Recurring topics across this work include Cancer Immunotherapy and Biomarkers (17 papers), Colorectal Cancer Treatments and Studies (13 papers), Immune Cell Function and Interaction (11 papers), Lung Cancer Treatments and Mutations (8 papers), Extracellular vesicles in disease (8 papers), Gastric Cancer Management and Outcomes (7 papers), Inflammasome and immune disorders (6 papers) and NF-κB Signaling Pathways (6 papers). The work is most often cited by research in Immunology (817 citations), Oncology (896 citations), Cancer Research (369 citations), Complementary and alternative medicine (194 citations) and Molecular Biology (1.4k citations). Yanhong Gu has collaborated with scholars based in China, United States and Czechia. Frequent co-authors include Qiang Xu, Yang Sun, Wenjie Guo, Yan Shen, Yongqian Shu, Xingxin Wu, Peifen Cai, Xuefeng Wu, Wen Liu and Xudong Wu. Their work appears in journals such as Journal of Clinical Oncology, Biomedicine & Pharmacotherapy, Cell Death and Disease, Toxicology and Applied Pharmacology and Medicine.

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Shoichi HazamaBreakdown of academic impact, for papers by Wen PengBreakdown of academic impact, for papers by Zhi ZengBreakdown of academic impact, for papers by Min XuBreakdown of academic impact, for papers by Pankaj GuptaBreakdown of academic impact, for papers by Minjiang ChenBreakdown of academic impact, for papers by Pengfei YuBreakdown of academic impact, for papers by Shuai ZhangBreakdown of academic impact, for papers by Jinhua XuBreakdown of academic impact, for papers by Quansheng Zhou